Abstract: This invention relates to the field of ribonucleic acid (RNA) regulation of intracellular activity. In particular, the invention relates to compositions and methods of identifying and tracking specific intracellular RNAs. For example, a fluorescently tagged RNA probe may be tracked by in vivo live imaging throughout its intracellular lifetime in order to determine its purpose and identify regulatory targets to modify its effects. Alternatively, an RNA probe may carry a therapeutic payload for treatment of medical condition or disorder.

Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

Abstract: The inventive technology may include novel systems for regulation of the expression of bacterial genes through the introduction of antisense RNA (asRNA) that may disrupt expression of targeted pathogenic genes and/or their products (mRNA, proteins). In some embodiments, the inventive technology may include novel genetically engineered donor bacterial strains that are configured to efficiently and continuously deliver asRNA polynucleotides to a recipient pathogen and downregulate expression or one or more essential genes.

Abstract: The technology described herein is directed to, e.g., methods of treating or preventing vascular calcification by modulating a novel calcification pathway which includes CROT, SLC20A1, PPAR?, HMOX1, STAT1, STAT3, and p38.

Abstract: Disclosed herein are compounds, compositions, and methods for decreasing TIGIT mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate TIGIT associated diseases, disorders, and conditions.

Abstract: In light of a discovery that astroglial Kir4.1 in lateral habenula drives neuronal bursts in depression, the present disclosure provides a pharmaceutical agent and a method of use thereof for treating depression. The pharmaceutical agent can inhibit an activity of an astroglial potassium channel, and especially suppress expression or functionality of Kir4.1, in astrocytes in the lateral habenula of a subject so that bursting activity of neurons in the lateral habenula of the subject can be suppressed. The pharmaceutical agent can include a vector expressing a target nucleotide sequence in the astrocytes in the lateral habenula, whose expression is configured to suppress Kir4.1 expression by RNA interference, or to block Kir4.1 functionality by a dominant negative effect of a mutant Kir4.1 protein. The pharmaceutical agent can alternatively comprise a small molecule compound, or an active macromolecule such as an anti-Kir4.1 antibody, configured to directly inhibit the astroglial potassium channel activity.

Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.

Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

Abstract: The present disclosure provides, inter alia, meiotic drive genes derived from chromosome 3 of the fission yeasts Schizosaccharomyces kambucha and S. pombe and orthologs thereof. In certain embodiments, compositions, methods, and kits are provided for biasing organisms to express such genes and, optionally, to co-express one or more genes of interest in such organisms.

Abstract: The invention is related to an inducible promoter for improved and regulated gene expression, useful in synthetic biology and metabolic engineering. In particular, the present invention relates to a nucleotide sequence comprising the regulatory regions of an erythritol- and erythrulose-inducible promoter in yeast and uses thereof in an expression system thus allowing an improved and regulated gene expression and production of gene product.

Abstract: Materials and methods are provided for making soybean varieties that have altered oil composition as a result of mutations in the FAD3A, FAD3B, and FAD3C genes.

Abstract: The present invention provides an inbred corn line designated IJ7877, methods for producing a corn plant by crossing plants of the inbred line IJ7877 with plants of another corn plant. The invention further encompasses all parts of inbred corn line IJ7877, including culturable cells. Additionally provided herein are methods for introducing transgenes into inbred corn line IJ7877, and plants produced according to these methods.

Abstract: Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding phenylalanine ammonia lyase (PAL) proteins, polypeptides encompassing PAL proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.

Abstract: The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which inhibit the level of PK220 gene expression or activity, wherein a desired phenotype such as increased water use efficiency relative to a wild type control plant. The invention also relates to nucleic acid sequences and constructs useful such methods and methods of generating and isolating plants having decreased PK220 expression or activity.

Abstract: Provided herein are methods and compositions relating to administering light enriched for UV-B to a plant material to improve subsequent plant performance.

Abstract: Plant cells, plants, seeds and portions of plants modified or genetically engineered to have increased expression or activity of at least one protein selected from the group consisting of trehalose phosphate synthetase (TPS), trehalose phosphate phosphatase (TPP), Protein ALP1-like (At3g55350 or ALPL1), Glycosyltransferase 75D1 (UGT75D1), Cytochrome P450 709B2 (CYP709B2), Cytochrome P450 709B1 (CYP709B1) and Cytochrome P450 72A15 (CYP72A15) are provided herein. Also provided are methods of increasing plant resistance to herbicides and/or abiotic stress by increasing expression of at least one of trehalose phosphate synthetase (TPS), trehalose phosphate phosphatase (TPP), Protein ALP1-like (At3g55350 or ALPL1), Glycosyltransferase 75D1 (UGT75D1), Cytochrome P450 709B2 (CYP709B2), Cytochrome P450 709B1 (CYP709B1) or Cytochrome P450 72A15 (CYP72A15).

Abstract: Provided herein are engineered TSC2 polypeptides, and nucleic acid sequences encoding them, in which the ability of a serine residue to be phosphorylated is altered. In some aspects, the TSC2 serine residue cannot be phosphorylated (e.g., by substituting the serine residue with an alanine residue). In some aspects, the TSC2 serine acts as if it is constitutively phosphorylated (e.g., by substituting the serine residue with a glutamic acid residue). Also provided herein are engineered immune cells comprising altered TSC2 polypeptides or nucleic acid sequences encoding them, and methods of making and using such engineered immune cells.

Abstract: The present invention, in some embodiments thereof, is directed to a method for selecting a gender of an avian fertilized unhatched egg obtained from the crossing of a transgenic male avian subject and a transgenic female avian subject. Further provided is a kit for preparing a transgenic avian subject.

Abstract: Disclosed herein is a functional nucleic acid that includes i) one or more coding nucleotide sequences encoding a genome editing endonuclease; ii) regulatory sequences operably linked to the one or more coding nucleotide sequences; and iii) one or more genome editing endonuclease-recognized sequences, wherein the functional nucleic acid is configured to express the endonuclease in a host cell and thereby provide a cellular endonuclease activity in a sequence-specific manner in the host cell, and wherein cleavage of the functional nucleic acid by the endonuclease inactivates the cellular endonuclease activity. Methods of using the present functional nucleic acid, and systems and kits that find use in performing the same are also provided.

Abstract: Disclosed are methods of preparing FV vector particles. In some aspects, the disclosed methods may include the steps of transfecting a population of eukaryotic cells by contacting said population of eukaryotic cells with one or more transfection reagents to form a transfection mixture, and incubating the transfection mixture to form a transfected cell population; harvesting the FV vector particles from said transfected cell population; purifying the FV vector particles; and concentrating the FV vector particles.

Abstract: The disclosure includes a method of introducing a polynucleotide into a male germ cell or a Sertoli cell, comprising injecting an adeno-associated virus vector comprising the polynucleotide into the testis of a vertebrate.

Abstract: Provided are a recombinant herpes simplex virus, a preparation method and use thereof. The recombinant herpes simplex virus comprises a vector and foreign genes encoding at least two cytokines, wherein the vector is a herpes simplex virus with genes encoding ICP34.5 and ICP47 deleted, and optionally with at least one of genes encoding ICP6, TK and UNG deleted, and the insertion site/sites of the foreign genes is in at least one of the positions where the genes encoding ICP34.5, ICP47, ICP6, TK and UNG are deleted in the vector.

Abstract: The present invention relates to viral vectors and methods of their production and use.

Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Abstract: Provided are methods and compositions for genome editing using a delivery vehicle with multiple payloads. In some embodiments the delivery vehicle includes a payload that includes (a) one or more sequence specific nucleases that cleave the cell's genome or one or more nucleic acids encoding same, (b) a first donor DNA, which includes a nucleotide sequence that is inserted into the cell's genome, where insertion of said nucleotide sequence produces, in the cell's genome at the site of insertion, a target sequence (e.g., an attP site) for a site-specific recombinase; (c) the site-specific recombinase (or a nucleic acid encoding same) (e.g., ?C31, ?C31 RDF, Cre, FLP), where the site-specific recombinase recognizes said target sequence; and (d) a second donor DNA, which includes a nucleotide sequence that is inserted into the cell's genome as a result of recognition of said target sequence by the site-specific recombinase.

Abstract: The present specification relates to a transformed yeast strain capable of simultaneously utilizing xylose and glucose as carbon sources, a preparation method thereof and a biofuel production method using the same. The transformed yeast strain transforms a wild-type yeast strain incapable of using xylose as a carbon source and simultaneously convert glucose and xylose, thereby enabling high yield production of a biofuel. The economics and sustainability of the biofuel and biomaterial production processes can be highly enhanced by providing a strain which can easily be converted to a strain capable of producing a biofuel/material in a high yield through an additional modification.

Abstract: A therapeutic serum suitable for inclusion in a cosmetic preparation may be produced by stressing a co-culture including proliferative cells. The co-culture of cells may be obtained by growing first culture to less than one-hundred percent confluence on a surface. After a monolayer of first culture is established, a second culture may be seeded onto at least one cell free area on the surface, the resulting co-culture grown to less than one-hundred percent confluence. Additional cultures may then be seeded onto cell free areas of the surface and established until a monolayer having the desired population of cells is obtained. The monolayer is then stressed to obtain a serum by conditioning a collection medium. The obtained serum may be combined with a suitable cosmetic base to provide a cosmetic preparation.

Abstract: The invention relates to a process of fermenting plant material in a fermentation medium into a fermentation product using a fermenting organism, wherein one or more carbonic anhydrases are present in the fermentation medium.

Abstract: A process for the manufacture of butanol, acetone and other renewable chemicals utilizes one or more of by-products of the manufacture of malt whisky, such as pot ale and spent lees, biomass substrates, such as paper, sludge from paper manufacture and spent grains from distillers and brewers, and diluents, such as water and spent liquid from other fermentations. The process includes treating a substrate to hydrolyze it and fermenting the treated. Also provided is a biofuel including butanol manufactured according to the process.

Abstract: The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.

Abstract: The present invention relates to a variant of oleaginous yeast of the species Trichosporon oleaginosus characterized by mutations affecting cell wall synthesis that change the morphology thereof with respect to the wild-type strain of the same species. In particular, thanks to said mutations, cell aggregates are formed which, with respect to the wild-type strain of the same species, lower the viscosity of the culture broth, are more easily separable therefrom and thus make their recovery easier. Said variant of oleaginous yeast of the species Trichosporon oleaginosus is also characterized by yields of oleaginous cellular biomass and intracellular accumulation of lipids that are similar or even higher than those of the wild-type strain. Further, the present invention relates to a process for the production of lipids through said variant of oleaginous yeast of the species Trichosporon oleaginosus.

Abstract: The present invention discloses a method for producing a 1,2-amino alcohol compound by utilizing whole-cell transformation, and belongs to the technical field of gene engineering and microorganism engineering. According to the present invention, engineered Escherichia coli co-expresses epoxide hydrolase, alcohol dehydrogenase, ?-transaminase and glutamate dehydrogenase, is capable of realizing whole-cell catalysis of an epoxide in one step to synthesize a 1,2-amino alcohol compound, and meanwhile, can realize regeneration of coenzyme NADP+ and an amino doner L-Glu; alcohol dehydrogenase expressed by the engineered Escherichia coli is RBS optimized alcohol dehydrogenase, and such RBS optimization can control the expression quantity of alcohol dehydrogenase, so that the catalysis rate of alcohol dehydrogenase and transaminase can achieve an optimum ratio, to eliminate influence caused by a rate-limiting step in a catalyzing course.

Abstract: This disclosure relates to modified tryptophan synthase and more particularly to modified beta-subunits of tryptophan synthase. The disclosure further relates to cells expressing such modified subunits and methods of producing non-canonical amino acids.

Abstract: Provided are a recombinant microorganism comprising: a gene encoding a pyridoxine oxidase; and a gene encoding a pyridoxamine synthetase having an enzymatic activity of synthesizing pyridoxamine from pyridoxal, in which each of the gene encoding a pyridoxine oxidase and the gene encoding a pyridoxamine synthetase is introduced from outside of a bacterial cell, or is endogenous to the bacterial cell and has an enhanced expression, and a method of producing pyridoxamine or a salt thereof from pyridoxine or a salt thereof using the recombinant microorganism.

Abstract: Provided is a process for synthesizing a functionalized cyclic dithiocarbamate.

Abstract: The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

Abstract: Non-naturally occurring microorganisms are provided that produce C40 carotenoid compound(s), utilizing exogenously added enzyme activities. Methods of producing C40 carotenoid compounds in microbial cultures, and feed and nutritional supplement compositions that include the C40 carotenoid compounds produced in the microbial cultures, are also provided.

Abstract: The present invention relates to a method for producing a vitamin- and protein-rich product, to a food product containing the vitamin- and protein-rich product, and to a nutrient medium appropriate for said method on the basis of agricultural tributaries or food tributaries.

Abstract: Rapid methods that identify sepsis-causing bacteria or yeast aid the physician in critical therapeutic decision-making, thus decreasing patient mortality rates. The methods described herein employ plating microorganisms directly on to a MALDI-MS plate, adding concentrated formic acid, and identifying the microorganism by mass spectrometry. Optionally, an organic solvent may be combined with the formic acid, or added to the sample before or after the concentrated formic acid is added thereto. The methods enable direct extraction of proteins from microorganisms without the need for liquid protein extraction methods and yields positive identification results for gram-positive bacteria, gram-negative bacteria and yeast in minutes.

Abstract: The present invention provides for improved antimicrobial susceptibility testing and more specifically for improved rapid antimicrobial susceptibility testing of clinical samples for efficient and versatile analysis and reliable results.

Abstract: Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

Abstract: A method for sizing a DNA molecule is disclosed, which comprises the following steps of: providing a DNA sizing device, comprising: a cover substrate; a substrate disposed on the cover substrate and comprising a first hole and a second hole; and a first slit-like channel disposed between the cover substrate and the substrate, wherein two ends of the first slit-like channel respectively connects to the first hole and the second hole; loading a sample comprising a DNA molecule to the first slit-like channel through the first hole, wherein the DNA molecule moves in a direction from the first hole to the second hole; detecting and recording an intensity and an area of a distribution of the DNA molecule; and analyzing the intensity and the area to obtain the size of a DNA molecule.

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Abstract: This disclosure provides microwell capsule array devices. The microwell capsule array devices are generally capable of performing one or more sample preparation operations. Such sample preparation operations may be used as a prelude to one more or more analysis operations. For example, a device of this disclosure can achieve physical partitioning and discrete mixing of samples with unique molecular identifiers within a single unit in preparation for various analysis operations. The device may be useful in a variety of applications and most notably nucleic-acid-based sequencing, detection and quantification of gene expression and single-cell analysis.

Abstract: Methods, compositions and kits for capturing, detecting and quantifying mature small RNAs are provided herein. Embodiments of the methods comprise tailing both the 5? and 3? ends of mature small RNA by ligating a 5? ligation adaptor to the 5? end and polyadenylating the 3? end. Other embodiments comprise reverse transcribing the adaptor ligated, polyadenylated mature small RNA with a universal reverse transcription primer and amplifying the cDNA with universal primers.

Abstract: Described herein are systems and methods for multiplexed analysis of two or more targets in a test sample including a first set of particles including a first set of target-specific reagents and a first optically detectable identifier capable of emitting a first wavelength indicative of a first target, and at least one second set of particles including a second set of target-specific reagents and a second optically detectable identifier capable of emitting a second wavelength indicative of a second target; and at least one optically detectable reporter probe capable of constitutively emitting a third wavelength in response to reaction of the first set of target-specific reagents with the first target in the test sample and/or reaction of the second set of target-specific reagents with the second target in the test sample, wherein the first wavelength, the second wavelength, and the third wavelength are optically discernable from one another.

Abstract: Methods and compositions for nucleic acid amplification, detection, and genotyping techniques are disclosed. In one embodiment, a nucleic acid molecule having a target-specific primer sequence; an anti-tag sequence 5? of the target-specific primer sequence; a tag sequence 5? of the anti-tag sequence; and a blocker between the anti-tag sequence and the tag sequence is disclosed. Compositions containing such a nucleic acid molecule and methods of using such a nucleic acid molecule are also disclosed.

Abstract: Systems and methods for detecting a target species using a semiconductor nanosensor are generally described.

Abstract: Low non-specific binding supports and formulations for performing solid-phase nucleic acid hybridization and amplification are described that provide improved performance for nucleic acid detection, amplification, and sequencing applications. These supports exhibit a high Contrast-to Noise Ratio (CNR), facilitating more accurate data collection and more accurate sequence reads.